,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['thanks', 'congrat', 'destiny-breast03', 'breast']
 kicking off #asco22 breast orals: destiny-breast03 safety update: no new safety signals - most teaes low grade w t-dxd - fantastic presentation - congratulations to team and thanks to all who participated! 
Chief Scientific Officer, Sarah Cannon Research Institute; Thoracic Medical Oncology, Tennessee Oncology